DeveloGen Reports Positive Phase 1 Clinical Trial Results for DG3173

(PresseBox) ( Göttingen, )
DeveloGen AG, a privately held biopharmaceutical company developing novel therapeutics for the treatment of metabolic and endocrine diseases today reported positive results from a Phase 1 study for DG3173, a novel somatostatin analogue. The results of the study indicate that DG3173 has an excellent safety and tolerability profile at all doses administered.

The Phase 1 trial was designed as a randomized, double-blind, placebo controlled, single ascending dose study to assess the safety, tolerability and pharmacokinetic parameters of DG3173. In total, 72 healthy male volunteers received between 10 to 2000 micrograms of DG3173 or placebo via subcutaneous injection. All doses of DG3173 were safe and well tolerated; the maximal tolerated dose has not been reached. In addition, neither serious adverse events nor dose-related adverse events were observed. Most frequently reported adverse events included unspecific headaches in six cases. Furthermore, gastrointestinal events and local injection site reactions were reported in three cases, respectively. Observed adverse events were generally mild and resolved spontaneously.

Analysis of pharmacokinetic properties of DG3173 revealed maximal DG3173 plasma concentrations within one hour of administration and a proportional increase of exposure with dose. An exploratory analysis of plasma growth hormone levels was consistent with a suppression of growth hormone release by DG3173.

Dr. Cord Dohrmann, Chief Executive Officer of DeveloGen commented: "The results of this initial Phase 1 study further support our working hypothesis that DG3173 has a superior safety and tolerability profile compared to currently marketed somatostatin analogues. In addition, we demonstrated a favourable pharmacokinetic profile for DG3173 and generated preliminary data indicating that DG3173 is able to suppress growth hormone release in humans." Dr. Dohrmann continued: "Our extensive preclinical characterization of DG3173 in combination with these Phase 1 study results provide a solid basis for further development of DG3137 in various indications, in particular in acromegaly and carcinoid tumors as well as diabetic retinopathy."

About DG3173

DG3173 is a new chemical entity somatostatin analogue (SSA) based on its novel amino acid composition and its unique backbone cyclization technology used for stabilization of the peptide. During extensive preclinical testing, DG3173 has demonstrated a unique receptor binding and pharmacological profile which is significantly differentiated from SSAs that are currently marketed or in clinical development. In particular, DG3173 has demonstrated an improved side effect profile with minimal adverse effects on the gastrointestinal tract and metabolic control. Furthermore, assessment of growth hormone secretion in cultured human somatotroph adenoma tissue treated with DG3173 suggests that it has the potential to significantly increase the response rate of acromegalic patients to SSA therapy. These preclinical and clinical results position DG3173 as best-in-class SSA in a market that currently generates more than US$ 1 billion in sales annually.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an